
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical Corp has demonstrated significant growth in payer access, expanding coverage from approximately 30% of commercial lives in May to about 65% by July, which translates to over 100 million lives. Additionally, the company has seen a remarkable increase in prescriber adoption, rising from around 660 in the first quarter to more than 1,800 by the second quarter, underscoring its rapid market traction. Furthermore, Journey's established brand value, particularly with products like Accutane, supports consumer retention and strengthens its ability to maintain market share in the competitive dermatological sector.
Bears say
Journey Medical Corp's stock faces a negative outlook primarily due to a significant decline in prescriptions for Accutane, which dropped to approximately 66,000 in Q1 2025 from 93,000 in the same quarter of 2024. Additionally, ongoing risks such as competitive pressures from both branded and generic treatments for rosacea, potential delays in the uptake of Emrosi, and various regulatory and clinical uncertainties contribute to the financial instability. The company may also encounter challenges regarding capital requirements if cash burn surpasses current projections, impacting overall financial health.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares